ChemoCentryx, Inc. (NASDAQ:CCXI) headquartered in Mountain View, will host a conference call for the investment community to discuss the 3Q20 financial results on 9th November 2020 at 5:00 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.chemocentryx.com
Earnings Expectation
ChemoCentryx, Inc. clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.31 per share from revenue of $ 10.70 million. Looking ahead, the full year loss are expected at $ 0.73 per share on the revenues of $ 74.95 million.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
